141 related articles for article (PubMed ID: 12126721)
1. Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants.
Sutthent R; Chokephaibulkit K; Piyasujabul D; Vanprapa N; Roogpisuthipong A; Chaisilwatana P
J Clin Virol; 2002 Jul; 25(1):47-56. PubMed ID: 12126721
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
Kamkamidze G; Sullivan T; Charbonneau T
J Clin Virol; 2001 Aug; 22(1):143-8. PubMed ID: 11418362
[TBL] [Abstract][Full Text] [Related]
3. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.
Masquelier B; Chaix ML; Burgard M; Lechenadec J; Doussin A; Simon F; Cottalorda J; Izopet J; Tamalet C; Douard D; Fleury H; Mayaux MJ; Blanche S; Rouzioux C;
J Acquir Immune Defic Syndr; 2001 Jun; 27(2):99-104. PubMed ID: 11404530
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
Welles SL; Pitt J; Colgrove R; McIntosh K; Chung PH; Colson A; Lockman S; Fowler MG; Hanson C; Landesman S; Moye J; Rich KC; Zorrilla C; Japour AJ
AIDS; 2000 Feb; 14(3):263-71. PubMed ID: 10716502
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of short-term and long-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission.
Bhoopat L; Khunamornpong S; Lerdsrimongkol P; Sirivatanapa P; Sethavanich S; Limtrakul A; Gomutbuthra V; Kajanavanich S; Thorner PS; Bhoopat T
J Acquir Immune Defic Syndr; 2005 Dec; 40(5):545-50. PubMed ID: 16284530
[TBL] [Abstract][Full Text] [Related]
7. Effect of immediate neonatal zidovudine on prevention of vertical transmission of human immunodeficiency virus type 1.
Sirinavin S S; Phaupradit W; Taneepanichskul S; Atamasirikul K; Hetrakul P; Thakkinstian A; Panburana P
Int J Infect Dis; 2000; 4(3):148-52. PubMed ID: 11179918
[TBL] [Abstract][Full Text] [Related]
8. Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
Colgrove RC; Pitt J; Chung PH; Welles SL; Japour AJ
AIDS; 1998 Dec; 12(17):2281-8. PubMed ID: 9863870
[TBL] [Abstract][Full Text] [Related]
9. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
Dabis F; Bequet L; Ekouevi DK; Viho I; Rouet F; Horo A; Sakarovitch C; Becquet R; Fassinou P; Dequae-Merchadou L; Welffens-Ekra C; Rouzioux C; Leroy V;
AIDS; 2005 Feb; 19(3):309-18. PubMed ID: 15718842
[TBL] [Abstract][Full Text] [Related]
10. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
11. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention.
MMWR Recomm Rep; 1998 Jan; 47(RR-2):1-30. PubMed ID: 9461044
[TBL] [Abstract][Full Text] [Related]
12. Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants.
Prasitwattanaseree S; Lallemant M; Costagliola D; Jourdain G; Mary JY
Antivir Ther; 2004 Apr; 9(2):179-85. PubMed ID: 15134179
[TBL] [Abstract][Full Text] [Related]
13. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
Taha TE; Kumwenda NI; Hoover DR; Fiscus SA; Kafulafula G; Nkhoma C; Nour S; Chen S; Liomba G; Miotti PG; Broadhead RL
JAMA; 2004 Jul; 292(2):202-9. PubMed ID: 15249569
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
[TBL] [Abstract][Full Text] [Related]
15. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
Thior I; Lockman S; Smeaton LM; Shapiro RL; Wester C; Heymann SJ; Gilbert PB; Stevens L; Peter T; Kim S; van Widenfelt E; Moffat C; Ndase P; Arimi P; Kebaabetswe P; Mazonde P; Makhema J; McIntosh K; Novitsky V; Lee TH; Marlink R; Lagakos S; Essex M;
JAMA; 2006 Aug; 296(7):794-805. PubMed ID: 16905785
[TBL] [Abstract][Full Text] [Related]
16. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
Goudsmit J; Weverling GJ; van der Hoek L; de Ronde A; Miedema F; Coutinho RA; Lange JM; Boerlijst MC
AIDS; 2001 Nov; 15(17):2293-301. PubMed ID: 11698703
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
[TBL] [Abstract][Full Text] [Related]
18. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine.
Hanson IC; Antonelli TA; Sperling RS; Oleske JM; Cooper E; Culnane M; Fowler MG; Kalish LA; Lee SS; McSherry G; Mofenson L; Shapiro DE
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(5):463-7. PubMed ID: 10225228
[TBL] [Abstract][Full Text] [Related]
19. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
Venturi G; Romano L; Catucci M; Riccio ML; De Milito A; Gonnelli A; Rubino M; Valensin PE; Zazzi M
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):274-82. PubMed ID: 10385016
[TBL] [Abstract][Full Text] [Related]
20. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Moodley D; Moodley J; Coovadia H; Gray G; McIntyre J; Hofmyer J; Nikodem C; Hall D; Gigliotti M; Robinson P; Boshoff L; Sullivan JL;
J Infect Dis; 2003 Mar; 187(5):725-35. PubMed ID: 12599045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
